Furthermore, in HER-2-positive breast cancer, NFκB activation leads to apoptosis inhibition and resistance to therapy, and a combination of anti-HER-2/anti-NFκB treatment has been suggested as a possible therapeutic option in these cases [37]. Here, ERBB2 is linked to breast cancer.